Neuro-Oncology Reviews
Volume
28 Number 23
20 August 2026
Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 23, 20 August
Aman RA, Wayne TMLS, Hamdilah F, Adriantama MW.
Impact
of PD-1 inhibitor immunotherapy on survival in patients with newly
diagnosed and recurrent glioblastoma: a systematic review of
comparative evidence.
Folia
Med (Plovdiv). 2026 Aug 13;68(4). doi:
10.3897/folmed.68.e184377. PMID:
42677757. ˍ
Coppin FM, Cordero NM, Hus J, D'Amico RS.
The
scientific evolution of the Ommaya reservoir: a bibliometric
analysis.
J
Neurooncol. 2026 Aug 13;179(1):38. doi:
10.1007/s11060-026-05756-4. PMID:
42593704˰ ˍ
Cunningham J.
Early-Phase Research in
Pediatric Neuro-Oncology.
Pediatr
Blood Cancer. 2026 Aug 13:e70627. doi:
10.1002/1545-5017.70627. PMID:
42590978. ˍ
Bu F, Zeng S, Ma C, Zhang M.
p53
Pathway-Targeted Therapeutic Strategies in Glioblastoma: A
CNS-Specific Framework Integrating Therapeutic Resistance,
Molecular Stratification, CNS Pharmacology, and Clinical
Translation.
Drug
Des Devel Ther. 2026 Aug 14;20:509447. doi:
10.2147/DDDT.S509447. PMID:
42614981. ˍ
Zhang T, Chen N, Wang J, Yu SC.
Research
advances in the recurrence patterns of glioblastoma.
Biochim
Biophys Acta Rev Cancer. 2026 Aug 15;1881(5):189681.
doi:
10.1016/j.bbcan.2026.189681. PMID:
42603639˰ ˍ
Hewawasam Wadige KN, Goetti R.
Paediatric-type
diffuse low-grade gliomas: A pictorial review.
Neuroradiol
J. 2026 Aug 17:19714009261478303. doi:
10.1177/19714009261478303. PMID:
42608290˰ ˍ
Zhang H, Sun L, Yun Z, Yin X, Li Y, Wu J, Dong G.
Comparative
efficacy of therapeutic strategies for recurrent or refractory
glioblastoma: a systematic review and network meta-analysis.
Front
Neurol. 2026 Aug 20;17:1896062. doi:
10.3389/fneur.2026.1896062. PMID:
42694176. ˍ
Guo Q, Shen S, Zhang Z, Shan M, Pan B, Yu X, Chen Y.
Immune
niches in brain tumors: glial-immune cell interactions and spatial
microdomains.
Acta
Neuropathol Commun. 2026 Aug 18;14(1):170. doi:
10.1186/s40478-026-02373-0. PMID:
42613643. ˍ
Aquilanti E, Touat M, French P, Iavarone A, Capper D, Geurts M,
Rahman R, Verhaak R, Preusser M, van den Bent M, Wen PY.
Exploring
the landscape of targetable alterations in patients with
glioblastoma.
Nat
Rev Clin Oncol. 2026 Aug 19. doi:
10.1038/s41571-026-01190-7. PMID:
42618642˰ ˍ
MacDonald SJ, Drill M, Jayakrishnan PC, Sequeira RP, O'Brien TJ,
Jeffree RL, Monif M.
The Imbalance
Between Tumor Immunosurveillance and Tumor Immune Escape in
Glioblastoma.
Immunol
Cell Biol. 2026 Aug 19. doi:
10.1111/imcb.70153. PMID:
42619051. ˍ
Augello MA, Wnuk M, Bavisotto CC, Cappello F, Scalia F.
From
protection to progression: How CCT/TRiC shapes therapy-induced
senescence in Glioblastoma multiforme.
Biochim
Biophys Acta Mol Basis Dis. 2026 Aug 20:168421. doi:
10.1016/j.bbadis.2026.168421. PMID:
42624300. ˍ
Damodharan S, Wright-Nadkarni M, Abdelbaki MS, Dhall G.
Infant
Embryonal CNS Tumors: Molecular Insights and Treatment
Considerations for Contemporary Pediatric Neuro-Oncology.
Pediatr
Blood Cancer. 2026 Aug 20:e70624. doi:
10.1002/1545-5017.70624. PMID:
42622520. ˍ
Lauwens L, Zegers CML, Postma AA, Minniti G, Alapetite C,
Andratschke N, Berghoff A, Blomstrand M, Booth TC, Castellano A,
Chalmers AJ, Dankbaar JW, Delgado AF, Duerinck J, Ehret F, Erridge
SC, Franceschi E, Furtner J, Galldiks N, Harrabi SB, Høyer
M, Iannalfi A, Kazda T, Le Rhun E, Löbel U, Lombardi G,
Lütgendorf-Caucig C, Mankad K, Navarria P, Niyazi M, Nunes T,
Pons-Escoda A, Preusser M, Ramos A, Razis E, Roelofs E, Rudà
R, Savatovsky J, Sepúlveda JM, Sundgren PC, Timmermann B,
Troost EGC, Van der Hoorn A, Weber DC, Weller M, van den Bent MJ,
Lambrecht M, Smits M, Eekers DBP.
ESTRO,
ESNR and EORTC consensus-based definition for MRI abnormalities
after radiotherapy for intracranial central nervous system
tumours.
Neuro
Oncol. 2026 Aug 20:noag194. doi:
10.1093/neuonc/noag194. PMID:
42623110˰ ˍ